Search clinical trials for: BI 1358894 (A)

Total 11831 results

Boehringer Ingelheim

Completed

A Study to Test How Iclepertin is Taken up in the Blood of People With and Without Kidney Problems

Renal Insufficiency

Germany
Boehringer Ingelheim

Completed

A Study in Healthy People to Test How BI 425809 is Taken up in the Body When Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated

Dermatitis, Atopic

United States, Japan, Canada
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Diabetes Mellitus, Type 2

United States, Australia, Canada, Germany, Spain, Taiwan, Hungary, Poland, Korea, Republic of, Austria, New Zealand, United Kingdom, Czechia, Puerto Rico
Cartiheal (2009) Ltd

Completed

Evaluation of the Agili-C Biphasic Implant in the Knee Joint

Cartilage Diseases | Osteochondritis Dissecans

Czechia, Italy, Croatia, Hungary, Poland, Romania, Serbia, Slovenia
University of California, San Diego

Completed

Right Ventricular Hemodynamics Using Cardiac MRI in Patients COPD and OSA

Chronic Obstructive Pulmonary Disease | Obstructive Sleep Apnea | Overlap Syndrome

United States
Ryerson University

Completed

HIV Prevention for HIV-Negative Men Via Reduction of Social Anxiety

Substance Use | Social Anxiety

Canada
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male Subjects

Healthy
European Organisation for Research and Treatment...

Completed

BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors

Sarcoma | Breast Cancer | Head and Neck Cancer | Ovarian Cancer | Endometrial Cancer | Melanoma (Skin)

Belgium
University of Manitoba
Canadian IBD Research Consortium (CIRC)

Not yet recruiting

Bowel Preparation for Colonoscopy Among Individuals With Crohn's and Ulcerative Colitis Disease.

Crohn Disease | Ulcerative Colitis
Boehringer Ingelheim

Recruiting

A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine

Depressive Disorder, Major

United States
Erasmus Medical Center

Enrolling by invitation

Validation of SMS Protocol for HCC Screening in High-risk Patients

Hepatocellular Carcinoma

Netherlands
Boehringer Ingelheim

Completed

Spesolimab (BI 655130) Single Dose in Generalized Pustular Psoriasis

Psoriasis

Taiwan, Malaysia, France, Japan, Korea, Republic of, Tunisia
Boehringer Ingelheim

Completed

A Trial in Healthy Chinese Volunteers to Test How Different Doses of BI 655130 Are Taken up in the Body

Healthy

China
Boehringer Ingelheim

Completed

An Exploratory Maintenance Trial of BI 655064 in Patients With Lupus Nephritis

Lupus Nephritis

United Kingdom, Thailand, Germany, Japan, United States, Australia, Korea, Republic of, Hong Kong, Poland, Greece, Mexico, Czechia, Canada, Malaysia, Philippines, Portugal
Boehringer Ingelheim

Completed

A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2

Healthy

Japan
Biointegrator LLC

Terminated

Open-label Study of Safety, Tolerability and Pharmacokinetics of Multiple Doses of BI-CON-02 in Patients With HER2-positive Metastatic Breast Cancer, Previously Treated With Trastuzumab

Metastatic Breast Cancer

Russian Federation
Boehringer Ingelheim

Completed

Safety Tolerability and Pharmacokinetic of BI 411034

Healthy

Germany
Boehringer Ingelheim

Completed

Safety and Tolerability, Efficacy, Pharmacokinetic and Pharmacodynamic Study of Three Doses of BI 187004 Over 28 Days in Patients With Type 2 Diabetes Mellitus With and Without Metformin

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Terminated

To Investigate Safety, Tolerability, and Pharmacokinetics of Treatment With BI 660848 Rising Single Doses (From 2 mg to 600 mg) Administered as Oral Drinking Solution (Powder in Bottle).

Pain | Healthy

Germany
Chang Gung Memorial Hospital

Withdrawn

Efficacy of Unilateral Versus Bilateral Approach to Robot-Assisted Rehabilitation in Patients With Subacute Stroke

Subacute Stroke

Taiwan
Boehringer Ingelheim

Completed

This Study in Healthy Men and Women Tests How the Body Takes up BI 409306

Healthy

Germany
Boehringer Ingelheim

Recruiting

A Study to Test How BI 456906 is Taken up in the Blood of People With and Without Kidney Problems

Healthy | Renal Impairment

Germany
Boehringer Ingelheim

Completed

This Study in Healthy Men Tests How Different Doses of BI 894416 Are Taken up in the Body and How Well BI 894416 is Tolerated

Healthy

Germany
Boehringer Ingelheim

Completed

To Assess Safety, Tolerability and Pharmacokinetics of BI 730357 in Healthy Male Volunteers

Healthy Volunteers

Germany
Boehringer Ingelheim

Completed

Single Rising Doses of BI 655064 in Healthy Chinese and Japanese Male Volunteers

Healthy

Japan, Korea, Republic of
Boehringer Ingelheim

Terminated

Evaluation of Safety and Tolerability of Single Rising Doses of BI 473494 in Healthy Subjects

Healthy

Germany
Boehringer Ingelheim

Terminated

A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1

Cystic Fibrosis

United States, Spain, Belgium, Germany, Canada, United Kingdom, Sweden, France
Boehringer Ingelheim

Completed

A Study to Test How Well Healthy Men Tolerate Different Doses of BI 706321

Healthy

Germany
Manchester Metropolitan University
Manchester University NHS Foundation Trust

Unknown

Non Invasive Ventilation for Acute Exacerbations in Adult CF (NIVinCF)

Respiratory Failure | Cystic Fibrosis

United Kingdom
Boehringer Ingelheim

Completed

First in Man Trial of BI 113608

Healthy

Germany
Boehringer Ingelheim

Terminated

Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 137882 in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Study Evaluating Absorption, Distribution, Metabolism and Excretion (ADME) of Single Dose [14C]-BI 207127 in Healthy Male Volunteers

Healthy

United States
US Department of Veterans Affairs

Completed

Veterans Intensive Personalized Treatment in Heart Failure (VIP)

Heart Failure

United States
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BI 44370 BS Administered as an Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple, Rising Oral Doses of BI 11634 Oral Solution in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 44847 Powder in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Withdrawn

Safety and Pharmacokinetics of Multiple Rising Oral Doses of BI 224436 in Healthy Male Volunteers.

HIV Infections | Healthy
Boehringer Ingelheim

Completed

BI 207127 / Faldaprevir Combination Therapy in Hepatic Impairment (Child-Pugh B) Patients With Genotype 1b Chronic Hepatitis C Infection: HCVerso3

Hepatitis C, Chronic

United States, Germany, Spain, United Kingdom
Northwestern University
National Cancer Institute (NCI); National Comprehensive Cancer Network

Withdrawn

Volasertib and Vincristine Sulfate Liposome in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Recurrent Adult Acute Lymphoblastic Leukemia | Refractory Adult Acute Lymphoblastic Leukemia

United States
Inreda Diabetic B.V.
Stichting Robopump; Rijnstate ziekenhuis; Kinder Diabetes Centrum Nijmegen

Completed

Portable Artificial Pancreas Applied for Youth and Adolescents (PAPAYA 1)

Diabetes Mellitus, Type 1

Netherlands
Boehringer Ingelheim

Recruiting

A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

Schizophrenia

Korea, Republic of, Canada, United States, Taiwan, United Kingdom, Chile, Serbia, Brazil, China, Colombia, Germany, Greece, Italy, Japan, Mexico, Norway, Poland, Sweden, Spain, Argentina, Croatia, France, Slovakia, Denmark, Australia, Mal... and more
Boehringer Ingelheim

Active, not recruiting

CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

Schizophrenia

United States, United Kingdom, Taiwan, Germany, Bulgaria, Mexico, Argentina, Denmark, Korea, Republic of, Austria, China, Belgium, Czechia, Finland, Serbia, Brazil, Portugal, Lithuania
Universiteit Antwerpen

Completed

Impact of a Bi-annual CDTI on the Incidence of Epilepsy in an Onchocerciasis-endemic Area (OAETanzania)

Epilepsy | Onchocerciasis

Tanzania
University of Colorado, Denver
National Cancer Institute (NCI)

Completed

Improving Physical Activity Maintenance of Cancer Survivors

Cancer

United States
AbbVie
Boehringer Ingelheim

Completed

Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma

Asthma

United States, Korea, Republic of, Belgium, Taiwan, Canada, Germany, United Kingdom, France, Netherlands, Poland
Patri-cia Angelica de Miranda Silva Nogueira

Completed

CPAP Versus Bi-level in Chronic Heart Failure (CHF)

Heart Failure
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Multiple Rising Oral Doses of BI 1015550 Powder for Oral Solution

Healthy

Germany
St. Jude Children's Research Hospital

Completed

Constraint-Induced Movement Therapy in a Pediatric Oncology Population (SJCIT)

Brain Tumor | Hemiplegia

United States
University Hospital, Montpellier

Completed

Analgesic Non Inferiority of the Thoracic Bi-block in Comparison With Thoracic Epidural for VATS. (ANESSTEVATS)

Pleural Diseases | Analgesia | Lung Cancer | Enhanced Recovery After Surgery | Thoracic Epidural | Video-Assisted Thoracic Surgery | Erector Spinae Muscle Plane Block | Serratus Anterior Muscle Plane Block

France

Search clinical trials for: BI 1358894 (A)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Austria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations